Bronchial and Thymic Neuroendocrine Tumour

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Bronchial and Thymic Neuroendocrine Tumour trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT02146170

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapul…

Background: \- Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year. Researchers want to gathe…

United States2,000 participantsStarted 2014-05-28

All recent trials (12 shown)

CompletedNot Applicable

NCT05461430

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict res…

United States72 participantsStarted 2022-07-15

TerminatedPhase 1

NCT04234113

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizu…

United States, Czechia, France115 participantsStarted 2019-06-13

Treatment: Nanrilkefusp alfa, Pembrolizumab

Bronchial and Thymic Neuroendocrine Tumour

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapul…

All recent trials (12 shown)

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapul…

All recent trials (12 shown)

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma